Loading chat...
TN HB1984
Bill
Status
1/22/2026
Primary Sponsor
Timothy Hill
Click for details
AI Summary
-
Healthcare providers may directly administer buprenorphine mono products (without naloxone) on-site for substance use disorder treatment, but patients cannot take these products home for self-administration
-
Prescribers are prohibited from prescribing or dispensing buprenorphine mono products except for pregnant women, nursing mothers, patients with documented adverse reactions or hypersensitivity, or when prescribing injectable formulations
-
Amends Tennessee Code Annotated, Section 53-11-311, which governs buprenorphine prescribing requirements
-
Takes effect immediately upon becoming law
Legislative Description
AN ACT to amend Tennessee Code Annotated, Title 53, Chapter 11, relative to the use of buprenorphine products.
Controlled Substances
Last Action
Placed on cal. Health Committee for 3/17/2026
3/11/2026